Detection of Micrometastases in Lymph Nodes of Patients With Prostate Cancer
|ClinicalTrials.gov Identifier: NCT01615965|
Recruitment Status : Active, not recruiting
First Posted : June 11, 2012
Last Update Posted : July 28, 2015
|Condition or disease||Intervention/treatment|
|Prostate Cancer||Other: tumor marker detection in lymph nodes|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||160 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Detection of Micrometastases in Lymph Nodes of Patients With Prostate Cancer|
|Study Start Date :||February 2010|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2021|
Molecular biologic detection of micrometastases in lymph nodes of patients with localized prostate cancer treated with radical prostatectomy and lymphadenectomy.
Other: tumor marker detection in lymph nodes
tumor marker detection in lymph nodes by quantitative PCR
- Biochemical recurrence free survival [ Time Frame: 2 years ]Influence of molecularbiologic micrometastases in lymph nodes on biochemical recurrence free survival in comparison with patients who have histopathologic macrometastases or no evidence of lymph node metastases
- Frequency of molecular detected lymph node micrometastases according to their topography [ Time Frame: 2 years ]
Description of the anatomic distribution of molecularbiologic lymph node micrometastases in prostate cancer patients treated with radical prostatectomy and extended lymphadenectomy.
The frequency of molecular detected lymph node micrometastases according to their anatomic distribution at the obturatoric fossa, external iliac, internal iliac and common iliac arteries´ region will be reported.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01615965
|Munich, Germany, 81675|